Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. (Q38110693)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23722347%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23722347%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23722347%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Lars Jordheim

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23722347%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Fabien Zoulim

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23722347%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Charles Dumontet

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23722347%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

3

Fabien Zoulim

1 reference

29 August 2017

Lars Petter Jordheim

1

1 reference

29 August 2017

Charles Dumontet

4

1 reference

29 August 2017

publication date

1 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23722347%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Drug Discovery

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23722347%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23722347%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23722347%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

447-464

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23722347%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrd4010

2 March 2020

exact match

0 references

1 reference

Acyclovir: discovery, mechanism of action, and selectivity

31 March 2020

1 reference

A 40-year journey in search of selective antiviral chemotherapy

31 March 2020

1 reference

Antiviral acyclic nucleoside phosphonates structure activity studies

31 March 2020

1 reference

Acyclic nucleoside phosphonates: a key class of antiviral drugs

31 March 2020

1 reference

Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition

31 March 2020

1 reference

Drug uptake transporters in antiretroviral therapy

31 March 2020

1 reference

In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs

31 March 2020

1 reference

Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus

31 March 2020

1 reference

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

31 March 2020

1 reference

The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.

31 March 2020

1 reference

Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma

31 March 2020

1 reference

The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.

31 March 2020

1 reference

A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity.

31 March 2020

1 reference

Integrating pharmacogenetics into gemcitabine dosing--time for a change?

31 March 2020

1 reference

Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies

31 March 2020

1 reference

Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery

31 March 2020

1 reference

Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma

31 March 2020

1 reference

Deoxycytidine kinase is overexpressed in poor outcome breast cancer and determines responsiveness to nucleoside analogs

31 March 2020

1 reference

Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma

31 March 2020

1 reference

Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia

31 March 2020

1 reference

Clinical significance of high-Km 5'-nucleotidase (cN-II) mRNA expression in high-risk myelodysplastic syndrome

31 March 2020

1 reference

Improved syntheses of 5'-S-(2-aminoethyl)-6-N-(4-nitrobenzyl)-5'-thioadenosine (SAENTA), analogues, and fluorescent probe conjugates: analysis of cell-surface human equilibrative nucleoside transporter 1 (hENT1) levels for prediction of the antitumo

31 March 2020

1 reference

The HIVdb system for HIV-1 genotypic resistance interpretation

31 March 2020

1 reference

HIV-1 antiretroviral resistance: scientific principles and clinical applications

31 March 2020

1 reference

Hepatitis B virus resistance to nucleos(t)ide analogues.

31 March 2020

1 reference

Massively parallel pyrosequencing in HIV research

31 March 2020

1 reference

Whole genome pyrosequencing of rare hepatitis C virus genotypes enhances subtype classification and identification of naturally occurring drug resistance variants.

31 March 2020

1 reference

Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen

31 March 2020

1 reference

Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come

31 March 2020

1 reference

Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia

31 March 2020

1 reference

Pharmacogenomics and individualized drug therapy

31 March 2020

1 reference

Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study

31 March 2020

1 reference

8-Amino-adenosine inhibits multiple mechanisms of transcription

31 March 2020

1 reference

A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels

31 March 2020

1 reference

Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase

31 March 2020

1 reference

Inhibition of topoisomerase II by 8-chloro-adenosine triphosphate induces DNA double-stranded breaks in 8-chloro-adenosine-exposed human myelocytic leukemia K562 cells

31 March 2020

1 reference

8-Chloro-adenosine inhibits growth at least partly by interfering with actin polymerization in cultured human lung cancer cells

31 March 2020

1 reference

Fluorocyclopentenyl-cytosine with broad spectrum and potent antitumor activity.

31 March 2020

1 reference

Synthesis of 4'-thio-beta-D-arabinofuranosylcytosine (4'-thio-ara-C) and comparison of its anticancer activity with that of ara-C

31 March 2020

1 reference

A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies.

31 March 2020

1 reference

Long intracellular retention of 4'-thio-arabinofuranosylcytosine 5'-triphosphate as a critical factor for the anti-solid tumor activity of 4'-thio-arabinofuranosylcytosine

31 March 2020

1 reference

Inhibition of the subgenomic hepatitis C virus replicon in huh-7 cells by 2'-deoxy-2'-fluorocytidine.

31 March 2020

1 reference

Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication

31 March 2020

1 reference

Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine.

31 March 2020

1 reference

JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients

31 March 2020

1 reference

PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients

31 March 2020

1 reference

RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients

31 March 2020

1 reference

Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.

31 March 2020

1 reference

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

31 March 2020

1 reference

In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs

31 March 2020

1 reference

In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection

31 March 2020

1 reference

Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine

31 March 2020

1 reference

Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro

31 March 2020

1 reference

Retention of metabolites of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel anti-human immunodeficiency virus type 1 thymidine analog, in cells

31 March 2020

1 reference

Highlights in antiviral drug research: antivirals at the horizon

31 March 2020

1 reference

Progress in the development of new therapies for herpesvirus infections

31 March 2020

1 reference

Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections

31 March 2020

1 reference

Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility

31 March 2020

1 reference

Synthesis and biological activity of 2'-deoxy-4'-thio pyrimidine nucleosides

31 March 2020

1 reference

DNA containing 4'-thio-2'-deoxycytidine inhibits methylation by HhaI methyltransferase

31 March 2020

1 reference

Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy

31 March 2020

1 reference

Inhibition of DNA methylation and reactivation of silenced genes by zebularine

31 March 2020

1 reference

Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides

31 March 2020

1 reference

Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs

31 March 2020

1 reference

Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug.

31 March 2020

1 reference

The SATE pronucleotide approach applied to acyclovir: part II. Effects of bis(SATE)phosphotriester derivatives of acyclovir on duck hepatitis B virus replication in vitro and in vivo

31 March 2020

1 reference

Application of the cycloSal-prodrug approach for improving the biological potential of phosphorylated biomolecules

31 March 2020

1 reference

Study of the efficacy of a pronucleotide of 2-chloro-2'-deoxyadenosine in deoxycytidine kinase-deficient lymphoma cells

31 March 2020

1 reference

Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver

31 March 2020

1 reference

Liver-targeted drug delivery using HepDirect prodrugs

31 March 2020

1 reference

Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B.

31 March 2020

1 reference

Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma.

31 March 2020

1 reference

Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells

31 March 2020

1 reference

Activation of p16 gene silenced by DNA methylation in cancer cells by phosphoramidate derivatives of 2'-deoxyzebularine

31 March 2020

1 reference

Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus

31 March 2020

1 reference

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

31 March 2020

1 reference

Practical synthesis, separation, and stereochemical assignment of the PMPA pro-drug GS-7340.

31 March 2020

1 reference

Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340.

31 March 2020

1 reference

Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue

31 March 2020

1 reference

Stampidine is a potent inhibitor of Zidovudine- and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical human immunodeficiency virus type 1 isolates with thymidine analog mutations

31 March 2020

1 reference

Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS

31 March 2020

1 reference

Phospholipid-nucleoside conjugates. 3. Syntheses and preliminary biological evaluation of 1-beta-D-arabinofuranosylcytosine 5'-monophosphate-L-1,2-dipalmitin and selected 1-beta-D-arabinofuranosylcytosine 5-diphosphate-L-1,2-diacylglycerols.

31 March 2020

1 reference

Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126

31 March 2020

1 reference

CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines

31 March 2020

1 reference

Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs

31 March 2020

1 reference

Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1.

31 March 2020

1 reference

Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines

31 March 2020

1 reference

Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.

31 March 2020

1 reference

Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine.

31 March 2020

1 reference

Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue

31 March 2020

1 reference

Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor

31 March 2020

1 reference

Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer

31 March 2020

1 reference

Synthesis of n-squalenoyl cytarabine and evaluation of its affinity with phospholipid bilayers and monolayers

31 March 2020

1 reference

Improved plasma stability and sustained release profile of gemcitabine via polypeptide conjugation.

31 March 2020

1 reference

Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid

31 March 2020

1 reference

188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases

31 March 2020

1 reference

A conjugate of gemcitabine with bisphosphonate (Gem/BP) shows potential as a targeted bone-specific therapeutic agent in an animal model of human breast cancer bone metastases

31 March 2020

1 reference

Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model

31 March 2020

1 reference

5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2.

31 March 2020

1 reference

Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.

31 March 2020

1 reference

Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base

31 March 2020

1 reference

Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers

31 March 2020

1 reference

Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy

31 March 2020

1 reference

Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study

31 March 2020

1 reference

Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine

31 March 2020

1 reference

Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells

31 March 2020

1 reference

Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors

31 March 2020

1 reference

In vitro and in vivo studies of pharmacokinetics and antitumor efficacy of D07001-F4, an oral gemcitabine formulation

31 March 2020

1 reference

Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase.

31 March 2020

1 reference

Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia

31 March 2020

1 reference

The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients

31 March 2020

1 reference

Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma

31 March 2020

1 reference

Effects of Lipid Composition and Preparation Conditions on Physical-Chemical Properties, Technological Parameters and In Vitro Biological Activity of Gemcitabine-Loaded Liposomes

31 March 2020

1 reference

Superior preclinical efficacy of gemcitabine developed as chitosan nanoparticulate system

31 March 2020

1 reference

Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity.

31 March 2020

1 reference

First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.

31 March 2020

1 reference

Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment.

31 March 2020

1 reference

In vivo antitumor activity of 9-[(2-phosphonylmethoxy)ethyl]-guanine and related phosphonate nucleotide analogues

31 March 2020

1 reference

Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro

31 March 2020

1 reference

Targeting DNA repair in chronic lymphocytic leukemia cells with a novel acyclic nucleotide analogue, GS-9219.

31 March 2020

1 reference

Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks

31 March 2020

1 reference

Trifluorothymidine resistance is associated with decreased thymidine kinase and equilibrative nucleoside transporter expression or increased secretory phospholipase A2.

31 March 2020

1 reference

TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial

31 March 2020

1 reference

Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine

31 March 2020

1 reference

Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine

31 March 2020

1 reference

Antibacterial activity and mechanism of action of 3'-azido-3'-deoxythymidine (BW A509U)

31 March 2020

1 reference

Mechanisms of zidovudine resistance in bacteria.

31 March 2020

1 reference

Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains.

31 March 2020

1 reference

Gemcitabine is active against clinical multiresistant Staphylococcus aureus strains and is synergistic with gentamicin.

31 March 2020

1 reference

Non-[18F]FDG PET in clinical oncology

31 March 2020

1 reference

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

31 March 2020

1 reference

Delayed treatment with an adenosine kinase inhibitor, GP683, attenuates infarct size in rats with temporary middle cerebral artery occlusion

31 March 2020

1 reference

Adenosine transport blockade restores attenuated cardioprotective effects of adenosine preconditioning in the isolated diabetic rat heart: potential crosstalk with opioid receptors

31 March 2020

1 reference

31 March 2020

1 reference

Molecular strategies to inhibit the replication of RNA viruses

31 March 2020

1 reference

Henipavirus outbreaks to antivirals: the current status of potential therapeutics

31 March 2020

1 reference

Analysis of Ribavirin Mutagenicity in Human Hepatitis C Virus Infection

31 March 2020

1 reference

Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications

31 March 2020

1 reference

Nucleoside analogs: molecular mechanisms signaling cell death.

31 March 2020

1 reference

Radiosensitizing nucleosides

31 March 2020

1 reference

Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome

31 March 2020

1 reference

A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies

31 March 2020

1 reference

A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors

31 March 2020

1 reference

A novel transcriptional inhibitor induces apoptosis in tumor cells and exhibits antiangiogenic activity.

31 March 2020

1 reference

A novel anticancer agent ARC antagonizes HIV-1 and HCV.

31 March 2020

1 reference

Nucleoside analog ARC targets Mcl-1 to induce apoptosis in leukemia cells

31 March 2020

1 reference

Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus

31 March 2020

1 reference

Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of

31 March 2020

1 reference

Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.

31 March 2020

1 reference

Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients

31 March 2020

1 reference

Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection

31 March 2020

1 reference

Special feature of mixed phosphotriester derivatives of cytarabine

31 March 2020

1 reference

Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug

31 March 2020

1 reference

Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial

31 March 2020

1 reference

INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties.

31 March 2020

1 reference

Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia

31 March 2020

1 reference

Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia

31 March 2020

1 reference

Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: An original drug delivery pathway

31 March 2020

1 reference

S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth

31 March 2020

1 reference

Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides

31 March 2020

1 reference

Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections

31 March 2020

1 reference

First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses

31 March 2020

1 reference

8-amino-adenosine is a potential therapeutic agent for multiple myeloma.

31 March 2020

1 reference

12 December 2020

Review of recent studies on resistance to cytotoxic deoxynucleoside analogues

1 reference

12 December 2020

N4-Behenoyl-1-beta-D-arabinofuranosylcytosine as a potential new antitumor agent

1 reference

12 December 2020

Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity.

1 reference

12 December 2020

8-chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells

1 reference

12 December 2020

Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy

1 reference

12 December 2020

Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs

1 reference

12 December 2020

Self-assembled squalenoyl-cytarabine nanostructures as a potent nanomedicine for treatment of leukemic diseases.

1 reference

12 December 2020

Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models

1 reference

12 December 2020

A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells

1 reference

12 December 2020

Preclinical antitumor activity of 4'-thio-beta-D-arabinofuranosylcytosine (4'-thio-ara-C).

1 reference

12 December 2020

588 IN VITRO ANTIVIRAL ACTIVITY AND PHARMACOLOGY OF IDX184, A NOVEL AND POTENT INHIBITOR OF HCV REPLICATION

1 reference

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/NRD4010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23722347%20AND%20SRC:MED&resulttype=core&format=json

release_nuswdissfbdw3e4iypruujwtv4

2 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nuswdissfbdw3e4iypruujwtv4

24 November 2022

mapped directly with Wikidata item

1 reference